4-Star Stocks Poised to Pop: SciClone Pharmaceuticals
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company SciClone Pharmaceuticals has earned a respected four-star ranking.
With that in mind, let's take a closer look at SciClone's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Foster City, Calif. (1989)|
|Market Cap||$326.5 million|
|Trailing-12-Month Revenue||$158.3 million|
|Management||CEO Dr. Friedhelm Blobel (since 2006)|
CFO Gary Titus (since 2008)
|Return on Equity (average, past 3 years)||23.4%|
|Cash/Debt||$81.6 million / $2.5 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 93% of the 165 members who have rated SciClone believe the stock will outperform the S&P 500 going forward.
What I do like about SciClone is that they've been solidly profitable for the last three quarters and they're using profits to build a stronger cash position. Since dilution seems to be a much more prevalent source of pipeline funding in the baby biotech sector, profitability always gets my attention. The remnants of SciClone's pipeline seem to have died out so a new acquisition is a substantial possibility.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, SciClone may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow theTrackPoisedToCAPS account.
The article 4-Star Stocks Poised to Pop: SciClone Pharmaceuticals originally appeared on Fool.com.Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Gilead. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.